1. Home
  2. AEMD vs XRTX Comparison

AEMD vs XRTX Comparison

Compare AEMD & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aethlon Medical Inc.

AEMD

Aethlon Medical Inc.

N/A

Current Price

$5.47

Market Cap

3.9M

Sector

Health Care

ML Signal

N/A

Logo XORTX Therapeutics Inc.

XRTX

XORTX Therapeutics Inc.

N/A

Current Price

$0.90

Market Cap

3.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AEMD
XRTX
Founded
1984
2011
Country
United States
Canada
Employees
9
N/A
Industry
Medical/Dental Instruments
Pharmaceuticals and Biotechnology
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.9M
3.9M
IPO Year
2008
2018

Fundamental Metrics

Financial Performance
Metric
AEMD
XRTX
Price
$5.47
$0.90
Analyst Decision
Hold
Analyst Count
2
0
Target Price
★ $13.25
N/A
AVG Volume (30 Days)
54.1K
★ 359.6K
Earning Date
11-16-2026
11-20-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$392.31
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.53
$0.35
52 Week High
$25.66
$3.60

Technical Indicators

Market Signals
Indicator
AEMD
XRTX
Relative Strength Index (RSI) 52.35 31.70
Support Level $4.86 $0.83
Resistance Level $6.69 $1.15
Average True Range (ATR) 0.39 0.12
MACD -0.03 0.01
Stochastic Oscillator 45.61 20.97

Price Performance

Historical Comparison
AEMD
XRTX

About AEMD Aethlon Medical Inc.

Aethlon Medical Inc is a medical therapeutic company focused on developing the Hemopurifier (HP), a clinical-stage investigational immunotherapeutic device designed to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation and other disease states in which extracellular vesicles (EVs) contribute to disease progression. The Hemopurifier utilizes a proprietary lectin-based technology to bind and remove enveloped viruses and EVs from biological fluids. EVs have been associated with immune suppression, metastasis, and resistance to therapy in cancer, as well as progression of severe infectious diseases. The Company operates as a single reportable segment.

About XRTX XORTX Therapeutics Inc.

XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.

Share on Social Networks: